A Phase 1 Two-Arm, Randomized, Double-blind, Active-controlled Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs PXVX0047 (Primary) ; DR 5001
- Indications Adenovirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors PaxVax
- 25 May 2018 Status changed from recruiting to discontinued as new formulation to be tested
- 24 May 2017 New trial record